Red Light Holland, through its subsidiary Filament Health, is supporting the Carhart-Harris Lab at UCSF by providing instructions for participation in the CHL Global Psychedelic Study to researchers and clinicians using Filament's pharmaceutical-grade psilocybin drug candidate, PEX010. This large-scale study aims to understand individual responses to psychedelics in natural settings and is open to anyone planning to use psychedelics. The collaboration leverages Filament's wide distribution network to access a diverse patient population, contributing real-world data to advance scientific knowledge and inform policy and medical communities on botanical psilocybin. This effort aligns with Red Light Holland's strategy to expand legal and responsible access to psychedelic therapies.
